After Lull In Biosimilar IP Litigation, 2021 Could Bring Influx

Law360 (January 7, 2021, 5:35 PM EST) -- A biosimilar is biological product that is highly similar to and has no clinically meaningful differences from an existing approved reference biological product.

Much like the Hatch-Waxman Act did for generic drugs decades ago, the Biologics Price Competition and Innovation Act, enacted in 2010 as part of the Affordable Care Act, established an abbreviated regulatory pathway and unique patent litigation framework for biosimilars in the U.S.

Through this pathway, the U.S. Food and Drug Administration approved the first biosimilar in 2015 and progressively approved more biosimilars each year. To date, the FDA has approved a total of 29 biosimilars, of which...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!